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The active pharmaceutical ingredient rotigotine—a dopamine agonist for the treatment of
Parkinson’s and restless leg diseases—was known to exist in only one polymorphic form since
1985. In 2008, the appearance of a thermodynamically more stable and signiﬁcantly less
soluble polymorph led to a massive batch recall followed by economic and public health
implications. Here, we carry out state-of-the-art computational crystal structure prediction,
revealing the late-appearing polymorph without using any prior information. In addition, we
predict a third crystalline form of rotigotine having thermodynamic stability between forms I
and II. We provide quantitative description of the relative stability and solubility of the
rotigotine polymorphs. Our study offers new insights into a challenging polymorphic system
and highlights the robustness of contemporary computational crystal structure prediction
during pharmaceutical development.
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Developing crystalline forms with desired physico-chemicalproperties1,2 is of signiﬁcant importance for the phar-maceutical industry. Yet this family of crystalline solids is
susceptible to the well-established phenomenon of polymorphism
originating in their complex energy landscapes with many close-
lying local minima3. Most of these experimentally obtainable
crystal-packing arrangements differ in their stability by less than
2–4 kJ mol−1 4. Despite the advances in crystallization techniques,
engineering molecular crystals during the drug development
process is a non-trivial task. Often unexpected polymorphs
emerge due to a complex interplay between thermodynamics and
kinetics. The disappearance of the previously known stable form
or sudden appearance5 of a more stable form can have severe
consequences. For instance, the new form may present properties
that are not suitable for the intended purpose leading to sig-
niﬁcant economic and public health repercussions5,6.
One recent example of a late-appearing polymorph is rotigo-
tine, the active substance of Neupro®—a transdermal patch used
in the treatment of Parkinson’s disease (PD) and restless legs
syndrome (RLS)7–9. It is estimated that about 6.3 million people
worldwide are living with PD while RLS has a prevalence of about
7–10% of the adult population worldwide. Rotigotine is a dopa-
mine agonist, stimulating the brain so that patients can control
their movement and have fewer signs and symptoms of Parkin-
son’s disease, such as stiffness and slowness of movement9. The
delivery system consists of a fully amorphous patch formulation
made of a molecular dispersion of rotigotine within a polymer
matrix. Until 2007, the only and long-known crystalline phase of
rotigotine was form I. In 2008, however, the promising clinical
use of Neupro® was interrupted after the appearance of
snowﬂake-like crystals within the patch10,11. This quality defect
led to a massive batch recall in March 2008 in Europe and an out-
of-stock situation in the United States. The unexpected crystal-
lization happened due to the appearance of a novel solid phase
with greatly enhanced thermodynamic stability. The new solid
was characterized as a conformational polymorph of rotigotine
and subsequently named form II10. The solubility of form II was
found to be more than eight times lower compared with form I—
a striking difference for polymorphism, where mostly solubility
ratios below two are observed3,12.
The consequences for the patients were dramatic as, for
instance, Neupro® patches remained unavailable in the United
States from 2008 to 2012, until the patch was properly refor-
mulated to a stable amorphous matrix. The current pharmaceu-
tical composition is devoid of any crystalline defects and ensures
therefore its therapeutic efﬁcacy, despite the existence of form II.
The discovery of a second crystalline polymorph is especially
astonishing for rotigotine as it is a commercial drug that was
known since the mid-eighties and was well investigated for dec-
ades before the discovery. No indication of the presence of a
second crystalline form was ever observed in the early years of
formulation development despite a polymorphism screening
done in the early 2000s. The antiviral compound ritonavir, which
is in fact the most cited example of disastrous polymorphism in
the pharmaceutical industry, shows a remarkable resemblance
with rotigotine since also here the polymorphism is conforma-
tional in nature. Moreover, the new form has a much higher
stability and hence much lower solubility with an instability of the
amorphous formulation as the most striking effect13.
The likelihood of such a late-appearing polymorph can
nowadays be assessed via computational molecular crystal
structure predictions (CSP), which yield the thermodynamical
stabilities for a variety of different crystal-packing arrange-
ments14. Computational CSPs provide an unbiased thermo-
dynamical landscape in contrast to experimental screenings. In
several cases these computational predictions have led to the
subsequent experimental discovery of a new polymorph15–17.
However, these predictions face many challenges because of the
high-dimensional nature of the crystallographic and conforma-
tional space of a given molecule. In addition, due to the very
similar stability of the different polymorphs, relative free energy
calculations with an accuracy of about 1 kJ mol−1 would be
needed. Regularly, the Cambridge Crystallographic Data Centre
(CCDC) organizes blind tests in order to determine the quality of
a variety of different CSP methods.18–20. In recent years, several
improvements have been made, especially for methods relying on
density-functional theory (DFT), in order to cope with the
increasing difﬁculty of these blind tests. We have recently shown
that a combination of the most successful crystallographic space
sampling from the latest blind test with a sophisticated ﬁrst-
principles energy-ranking approach yields excellent results across
all target systems of that blind test21. In addition, this approach
can be applied to large and complex systems of pharmaceutical
relevance.
In the present study, we demonstrate computational CSP is
capable of identifying the late-appearing polymorph of rotigotine
without prior information from experiments. Furthermore, we
show that our search led to the prediction of the new crystalline
form or polymorph, which was not seen before, with thermo-
dynamic stability lying between forms I and II. We outline
a step-by-step guide to CSP and the subsequent reliable energy
calculations, and provide detailed quantitative and qualitative
insights of relative stability and solubility of rotigotine polymorphs.
We highlight that the synergy between modern computational CSP
and ﬁrst-principles electronic-structure methods can be a viable
approach to obtain invaluable insights into the drug development,
and could have had a signiﬁcant impact on the case of rotigotine.
Results
Crystal structure prediction of rotigotine. The polymorphic
energy landscape for the 25 structures from step 3 of the applied
CSP procedure (see Methods) is shown in Fig. 1b with a cutoff of
25 kJ mol−1 from the discovered global minimum. Each point
corresponds to a local lattice energy minimum based on PBE+
NP energies. The structures of the two experimental polymorphs
have been published as single-crystal structures. The metastable
structure with P43 space-group symmetry (form I) appeared as
Private Communication to the Cambridge Structural Database in
200122, whereas the stable structure with P212121 space-group
symmetry (form II) as part of a Patent in 200923. In both single-
crystal structures, the thiophene rings randomly adopt one of the
two alternative orientations, related by a 180° rotation, which has
been modeled as disorder in the experimental structures. In the
calculations, the number of degrees of freedom had been
restricted to one molecule per asymmetric unit, so only fully
ordered crystal structures, corresponding to all thiophene rings
throughout the crystal adopting the same orientation, can be
generated. Indeed, in the CSP study each experimental poly-
morph is found twice, once with all thiophene rings in one
orientation and once with all thiophene rings in the alternative
orientation. As a result, the two most stable predicted structures
(blue circles) both correspond to form II, and the two structures
describing the disordered form I (red squares) are found to be
about 6 kJ mol−1 less stable than form II. We have included the
structural overlays, which show perfect agreement for all four
ordered structures, in the SI (Supplementary Fig. 2). Calculations
performed with larger supercells modeling explicitly disordered
structures, in which different thiophene rings in the same crystal
structure can adopt different orientations, conﬁrmed that the
orientations of the thiophene rings are randomly distributed over
the two alternatives. Hereafter, we will always use the 50%:50%
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average of the two respective conﬁgurations to describe the dis-
ordered forms I and II.
New crystalline form of rotigotine. The CSP also predicted a
new form with P32 space-group symmetry (green triangle),
denoted as predicted form III, lying between form I and form II
in the crystal landscape. Since the stability of form III falls
between the two experimentally observed forms, this structure is a
potential candidate for crystallization experiments. It is not
obvious from the comparison of the crystal structure of predicted
form III to the structures of forms I and II, how form III may be
crystallized. A successful crystallization experiment would have to
both inhibit the appearance of the substantially more stable form
II and promote the appearance of the predicted form III. All other
predicted structures are less stable than the experimentally
observed forms. We also observed that the number of structures
considered in steps 1 and 2 for rotigotine is much smaller than
the typical values shown in Fig. 1a. This is a common feature for
compounds that have only a few highly stable packings separated
from the other structures by a substantial energy gap. In such
cases, only a few structures fall into the target energy window,
even in step 1.
At a time where form II had not yet been discovered, the
energy landscape shown in Fig. 1b, would not only have ﬂagged
rotigontine as a compound with a missing, substantially more
stable crystal form, but also have provided a clear indication for
how to obtain that missing form. Form II is predicted to have
signiﬁcantly higher density than form I. By crystallization from
solution under pressure (see ref. 16), the energy gap between
forms I and II can thus be increased further. In such an
experiment it may be possible to cross the metastable zone width
of form II before the saturation concentration of form I is
reached, resulting in the crystallization of form II.
Relative polymorphic stabilities of rotigotine. The discussed
CSP approach provides an excellent sampling of conformational
and crystallographic spaces, however, a reliable calculation of rela-
tive polymorphic stabilities requires using higher levels of theory
than PBE+NP. Aiming at a robust quantum-mechanical
description of free energies, we performed a ﬁnal energy ranking
of the 25 predicted structures utilizing the approach introduced in
ref. 21. This method employs a robust hierarchical ﬁrst-principles
approach based on DFT by incorporating key physical contribu-
tions including many-body van-der-Waals dispersion interactions
(MBD), a sophisticated treatment of electron exchange and corre-
lation via a hybrid functional, and vibrational free energies within
the harmonic approximation. Furthermore, anharmonic effects to
the free energy could be considered by accounting for thermal
expansion via the quasi-harmonic approximation and the use of
Morse oscillators as discussed in ref. 21. We found that these effects
can modify relative stabilities on average by about 1 kJ/mol24.
Therefore, these effects should have an insigniﬁcant inﬂuence on
the presented results since rotigotine’s energy landscape is rather
sparse. It was shown that the PBE0 functional25 in combination
with the MBD model26,27 is able to describe relative stabilities for
several molecular crystals within 1 kJ mol−1 compared with
experimental observations17,28–30. Here we use this method for
calculating static energies, whereas geometry optimizations and
vibrational free energies were carried out at the PBE+MBD
level26,27,31, leading to an improved description of vibrational free
energies24. All calculations were performed using the all-electron
code FHI-aims32 (see the Methods section for more details). The
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Fig. 1 Crystal structure prediction of rotigotine. a Three-step crystal structure prediction. b Energy-density diagram for the top 25 computer-generated
polymorphs based on PBE+NP energetics of rotigotine normalized per molecule. c Unit cells of the two known forms I, II, and the predicted form III of
rotigotine. In the top panel, the σ is the standard deviation of energies at the corresponding step, and Δ is the energy window that the user typically
speciﬁes. The standard value of 4.2 kJ mol−1 (1 kcal mol−1) was used for rotigotine
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Crystallographic Information Files (CIF) as well as FHI-aims geo-
metry ﬁles of the optimized structures are available in Supple-
mentary Data 1. The PBE0+MBD energies were calculated for
all 25 structures. Supplementary Fig. 3 shows the comparison
of PBE+NP and PBE0+MBD energies for all the structures.
The vibrational free energy calculations were limited to forms I, II,
and predicted form III. A comparison of the obtained PBE+NP
and PBE0+MBD relative energies with explicitly disordered
structures is shown in Supplementary Fig. 4. It can be seen that the
stability ordering of forms I, II, and predicted form III are identical,
however, there are substantial differences in the relative energies. In
contrast, we observe different stability orderings for higher-energy
structures.
In order to assess the reliability and accuracy of the relative
stabilities calculated by DFT+MBD, we experimentally mea-
sured enthalpy differences between forms I and II, and the
solubility difference between the two forms. Figure 2a shows the
cumulative enthalpy curves obtained from differential scanning
calorimetry measurements (see the Methods section for more
details). The measured enthalpy difference between form I and
form II amounts to 7.5 kJ mol−1 as shown in the ﬁgure. The
calculated relative stability of the three rotigotine polymorphs
obtained by four methods of increasing sophistication is shown in
Fig. 2b. It is apparent that the ranking based on PBE0+MBD
total energy is in better agreement with the experimental relative
enthalpy than that of PBE+NP. However, these two methods do
not include vibrational contributions. In order to directly
compare our stability ranking with the relative enthalpy from
the experiment, we add the harmonic vibrational internal energy
Uvib to the PBE0+MBD lattice energies, yielding the PBE0+
MBD+Uvib ranking. The Uvib is deﬁned as EZPE þ
R
CVdT ,
where EZPE is the zero-point energy while CV and T stand for the
heat capacity and temperature, respectively. It is noted that a pV
term is not included as its impact on the rankings at ambient
conditions is negligible.
This results in a stability difference of 7.6 kJ mol−1 between
form I and II, which is in excellent agreement with the
experimental value of 7.5 kJ mol−1. This result further suggests
the signiﬁcance of employing rigorous energy calculations after
the initial CSP, as the relative enthalpy estimation by PBE+NP,
used during CSP procedure, is 18% off from the experiment (see
the CSP ranking in Fig. 2b).
Going from relative enthalpies to relative Helmholtz free
energies at 300 K (see PBE0+MBD+Fvib ranking in Fig. 2b) does
not affect our conclusions. The vibrational free energy (Fvib)
contributions close the gap between form I and form II by more
than 2 kJ mol−1, while form III remains more stable than form I.
In order to elucidate the origin of this free energy change, we
calculated the relative PBE0+MBD+Fvib energies by considering
for Fvib only contributions of the phonon density of states up to
certain wave numbers (see Fig. 2c). The relative stabilities are
normalized to the most stable structure (form II) and approach at
high frequency the full PBE0+MBD+Fvib results. One can
observe that the relative stabilities are ﬂuctuating in the low-
frequency region but already nearly converge to the ﬁnal PBE0
+MBD+Fvib values after considering vibrations up to about 160
cm−1. This clearly shows that the relative free energies are
dominated by low-frequency vibrations. The phonon modes in
this frequency range consist mostly of intermolecular translations
and rotations, for which an accurate treatment of van-der-Waals
dispersion interactions provided by the MBD method is crucial.
The low-frequency phonon densities of states are shown in
Supplementary Fig. 5. All three polymorphs have distinct
vibrational spectra in the THz regime. These differences in the
low-frequency vibrations are utilized in THz spectroscopy to
detect certain explosives and drugs, as well as to experimentally
distinguish between polymorphs33.
Relative polymorphic solubility of rotigotine. A crucial property
of an active pharmaceutical ingredient is its solubility, which can
differ signiﬁcantly between different polymorphs as it is linked to
the free energy of the crystalline form. The measured solubility of
form I is nearly 8.4 times larger than that of form II at room
temperature in ethanol. The solubility ratio of two polymorphs in
the same solvent can be calculated from their free energies as KI/
KII= exp[−ΔF/RT], where ΔF is the free energy difference, and R
and T are gas constant and temperature, respectively. This follows
directly from the deﬁnition of the equilibrium constant, K= exp
[−ΔF 0/RT], and the observation that the free energy of the
solution is independent of the polymorph. We outline the deri-
vation of this equation in the Supplementary Discussion. Using
the estimated −5.28 kJ mol−1 for the free energy difference at
room temperature based on PBE0+MBD+ Fvib (see Fig. 2b), we
obtain a solubility ratio of 8.3 for form I/form II, which is in
excellent agreement with the experimental measurements. The
summary of our results along with experimental measurements
are tabulated in Table 1.
Discussion
We have demonstrated that a contemporary computational CSP
method reveals the late-appearing polymorph of rotigotine, and is
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capable of correctly describing complex polymorphic energy
landscapes of pharmaceutically relevant compounds. Further-
more, we predicted a potential new form of rotigotine with a
relative stability between form I and II. The obtained result of
computational CSP could, if they were available at the time of the
drug development of rotigotine, have led to additional efforts to
ﬁnd the predicted stable form, thus avoiding the dramatic late
appearance during production.
In addition, we have shown that modern ﬁrst-principles elec-
tronic-structure methods (the DFT+MBD framework) can be
used to determine the relative enthalpies and relative solubilities
of polymorphs in unprecedented agreement with experimental
measurements (see Table 1). The computational description of
the solubility is especially challenging since it does not only
require the correct description of the enthalpy but also accurate
vibrational entropies.
It has recently been shown in a metastudy over 41 commercial
crystal structure predictions of pharmaceutical compounds that
the thermodynamically stable form is expected to be missing in
15–45% of the cases34. The accurate results—within experimental
precision—obtained for rotigotine with respect to both poly-
morphic enthalpy difference and relative solubility difference
suggest that the DFT+MBD framework has the potential to
conﬁrm and narrow down this range, to pinpoint candidates for
late-appearing polymorphs more clearly, and to assess the max-
imum relative solubility drop to be expected in case of a
disappearing-appearing-polymorph event, thus providing crucial
quantitative information for risk management when developing
pharmaceuticals.
Methods
Crystal structure prediction within GRACE. The crystal structure prediction
(CSP) for rotigotine was performed using GRACE 2.4 software package35 without
using any a priori knowledge from experiments. The procedure is discussed in
detail in the Supplementary Information (see Supplementary Note 1) and consists
of two parts (see Supplementary Fig. 1): (i) a tailor-made force ﬁeld36 is para-
meterized from scratch with the Force Field Factory module and (ii) the actual CSP
is performed within the CSP Factory module36. The CSP Factory uses a three-step
procedure for each Z′ value considered (Z′ is the number of molecules in the
asymmetric unit) as shown in Fig. 1a. It is noted that all single bonds shown in
Fig. 1a were treated as independent degrees of freedom in the crystal structure
generation. First, crystal structures are generated with the tailor-made force ﬁeld
by a Monte Carlo parallel tempering algorithm (step 1). Promising candidates
are subjected to a dispersion-corrected density-functional theory (DFT-D)
lattice energy optimization. In this case the Perdew-Burke-Ernzerhof (PBE)31
functional is used together with the Neumann-Perrin (NP) dispersion model37.
These optimizations are performed with the Vienna Ab initio Simulation Package
(VASP)38–40 using loose convergence settings (step 2). Finally, the most promising
candidates from step 2 undergo a second PBE+NP lattice energy optimization with
tighter convergence settings (step 3). Statistical methods are used to control the
completeness of the three-step procedure by looking at the standard deviations
σ1 and σ2 obtained for the force-ﬁeld energies of the ﬁrst step and the coarse
DFT-D energies of the second step, respectively.
All DFT-D calculations were carried out with the PBE functional31 and the
dispersion correction according to Neumann-Perrin37. DFT calculations use a
plane wave cutoff energy of 520 eV and a k-point spacing of roughly 0.07/Å. All
lattice energy minimizations of the ﬁnal step have been converged to within at least
0.003 Å for atomic displacements, 0.00025 kcal mol−1/atom for energy changes,
0.7 kcal mol−1/Å for atomic forces and 1.0 kbar for cell stress. In the second step,
lattice energies are converged to within at least 0.02 Å for atomic displacements,
0.001 kcal mol−1/atom for energy changes, 7.0 kcal mol−1/Å for atomic forces, and
15.0 kbar for cell stress.
Crystal structures were generated with one molecules per asymmetric unit
(Z′= 1). According to the statistics of the Cambridge Structural Database (CSD)41,
87.8% of the crystal structures of chiral molecules, as rotigotine is, contain one
molecule per asymmetric unit. For molecules such as rotigotine, searches with two
molecules per asymmetric unit (Z′= 2) are technically feasible and often
economically reasonable, but in this case the search range was deliberately limited
to one molecule per asymmetric unit. For molecules of the size and ﬂexibility of
Rotigotine, it is because of the Z′= 2 part of the calculation that CSP is perceived
as an expensive computational technique. The CPU time cost of CSP grows
exponentially with the number of degrees of freedom, and the cost increase for
moving from Z′= 1 to Z′= 2 is roughly the same as for doubling the molecular
size and ﬂexibility at Z′= 1. However, since most observed structures crystallize
with only one molecule per asymmetric unit, many important results can already
be obtained by searches with Z′= 1 at a fairly acceptable cost, and the rotigotine
study provides an impressive demonstration of this fact. The crystal structure
generation was carried out in all chiral space groups. A value of Δ= 1.0 kcal mol−1
was chosen for the target energy window in which the completeness of the CSP
procedure is statistically controlled. Typically, many of the considered structures
fall outside this window and are reported in the ﬁnal results.
The tailor-made force ﬁeld was generated in 8 days, and actual CSP took 3 days.
For post-CSP calculations, it approximately took 8 CPU hours to fully optimize a
structure containing 188 atoms in the unit cell using PBE+MBD light setting, and
extra 2 CPU hours for energy calculations using PBE+MBD tight setting on 6
nodes, where each node has 16 cores, altogether summing up to 2 days for the three
main polymorphs, in addition to the CSP procedure (see Hardware details in the
next section)24. Table 4 in Ref. 24 shows relative computational cost for one single-
point energy and one force calculation for a particular molecular crystal containing
172 atoms in the unit cell, which allows an estimation of the total CPU time needed
for the free energy based on various methods.
The CSP calculations were carried out on 48 Intel Xeon CPUs E5-2670 2.6 GHz
8 core (=384 cores) with InﬁniBand network and 2 GB memory per core. The
postCSP free energy calculations were carried out at DRACO extension cluster at
the Max Planck Computing and Data Facility on Intel Haswell Xeon E5-2698
processors 2.3 GHz with InﬁniBand FDR14 network and 128 GB memory
per node.
Calculation of relative stabilities with the DFT+MBD framework. All DFT+
MBD calculations were performed by using the all-electron code FHI-aims32,42–47.
Full lattice and geometry optimizations were performed for all 25 polymorphs
using PBE+MBD26,27,31 with light species default settings for basis functions and
integration grids. The number of k-points n in each direction was determined by
the smallest integer for which n × a ≥ 28 Å, where a is the respective unit cell
length. For the optimizations we used a convergence criterion of 0.001 eV/Å for
force components.
For the stability ranking, we subsequently calculated the PBE0+MBD energy
as described in ref. 21. First, the PBE+MBD energy is calculated with fully
converged tight species default settings. Second, we add the difference between
PBE0+MBD and PBE+MBD calculated using light species default settings. This
provides a good approximation of converged PBE0+MBD energies at a much
smaller computational cost21.
The vibrational free energies were calculated within the harmonic
approximation by utilizing phonopy48 and ﬁnite displacements of 0.01 Å. All
necessary force calculations were performed with FHI-aims utilizing PBE+MBD
with light species default settings. The vibrational free energy was evaluated within
phonopy by using a fully converged q-point mesh.
Experimental determination of heat capacities and solubilities. Rotigotine
Form I and Form II were provided by UCB Pharma SA (Anderlecht, Belgium).
Ethanol was purchased from VWR (Darmstadt, Germany).
Solubility was determined by measurement of the rotigotine concentration of
the supernatant of a crystal suspension by the following procedure. Suspensions of
rotigotine in ethanol with a nominal concentration of about 1200 mgml−1 in case
of Form I and 200 mgml−1 in case of Form II were prepared in 1 ml HPLC vials
(Wicom, Heppenheim an der Bergstrae, Germany) and shaken overnight at 20 °C
(Thermomixer Eppendorf, Hamburg, Germany). The suspensions were then
centrifuged at 14,000 rpm for 10 min at 20 °C (Andreas Hettich GmbH, Tuttlingen,
Germany). The supernatant solutions were subsequently sampled, diluted and
subjected to HPLC analysis (Agilent 1100 VWD, Agilent, Waldbronn, Germany)
for concentration determination.
Differential Scanning calorimetry (DSC) was performed on a Mettler DSC822
(Mettler Toledo, Greifensee, Switzerland) connected to a refrigerated bath at 10 °C.
Nitrogen purge ﬂow was set at 50 ml min−1. Analysis was carried out with a
heating rate of 10 °C min−1 in pierced aluminum crucibles, from 30 up to 140 °C.
The DSC curves are shown in Supplementary Fig. 6.
The relative enthalpy difference between the two forms was derived from the
DSC signal by integration of the heat ﬂow signal into enthalpy49. To this purpose
the heat ﬂow signal was ﬁrst normalized with regard to the weight, then converted
to heat capacity (Cp) by division by the heating rate. Knowing that the original DSC
Table 1 Relative solubility of rotigotine, experiment
versus theory
Method ΔH (kJ mol−1) ΔF (kJ mol−1) ΔSolubility
Experiment 7.5 – 8.1
Theory 7.6 5.3 8.3
The relative enthalpy (ΔH), free energy (ΔF), and solubility between Form I and II of rotigotine
as obtained by our computational approach compared with experimental measurements
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measurements were not calibrated for absolute Cp determination and also knowing
that we are only interested in relative differences between the two forms, the Cp
curves were adjusted (only by vertical shifting and slope correction) to coincide in
the melt part of the curves above the melting point of Form II. In this temperature
region both forms will end up in the same molten state, irrespective of the original
crystalline form and will hence be in an identical state. Calculation of the enthalpy
curves was done by setting both forms arbitrarily to 0 J g−1 at 140 °C and
consecutive integration of the Cp curves from high to low temperature, thereby
reducing the enthalpy content of both forms while decreasing in temperature.
Following this procedure, the relative enthalpy difference between both forms
could be determined as a function of temperature. See Supplementary Discussion
for complimentary discussions.
Data availability
The data supporting the ﬁndings of this study are available within the article and its
Supplementary Information. The structure ﬁles in the format of Crystallographic
Information Files (CIF) and FHI-aims geometry are available in Supplementary Data 1.
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